BioPharmX enrolls patients to test new drug for skin condition rosacea

BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.

David Tierney, BioPharmX CEO expects the topline in this year, as he said in the announcement Monday.

“Unlike currently available therapies  which may further irritate a patient’s already sensitive skin, BPX-04—which utilizes our proprietary HyantX topical delivery system—was designed to improve the bioavailability of solubilized minocycline and enable a more targeted delivery to minimize irritation,” he explained.

Furthermore, he believes that, based on results from earlier studies, BPX-04 may provide an effective treatment for rosacea while minimizing the unwanted adverse effects associated with oral forms of antibiotics, as well as the tolerability limitations of topical treatments, thereby addressing an unmet need for 16 million patients in the US alone.